Table 3.
Influence of chalcones on MICFLC values determined for Candida albicans clinical isolates.
| Compound | MIC of FLC (μg/mL)a | |||
|---|---|---|---|---|
| B3 | B4 | Gu4 | Gu5 | |
| − | 1 | 16 | 4 | 256 |
| 5 | 1 | 4 | 4 | 256 |
| 6 | 1 | 16 | 4 | 32 |
| 11 | 0.5 | 1 | 2 | 128 |
| 15 | 1 | 8 | 4 | 64 |
| 18 | 1 | 2 | 4 | 32 |
| 19 | 1 | 8 | 4 | 256 |
| 20 | 1 | 16 | 4 | 128 |
| 21 | 1 | 2 | 4 | 64 |
| 22 | 1 | 16 | 4 | 128 |
| 23 | 1 | 8 | 4 | 128 |
| 25 | 1 | 8 | 4 | 128 |
| VPb | 1 | 0.5 | 4 | 64 |
| TFPb | 1 | 1 | 4 | 128 |
a
MIC values for FLC were determined by the serial dilution method as described Materials and Methods, in the presence of a fixed concentration of a compound tested (0.5 μg/mL for 11and 25 μg/mL for the other compounds).
b
Verapamil (50 μg/mL) and trifluoroperazine (20 μg/mL) were used as positive controls.
Cases of significant (>4-fold) MICFLC reduction by a given compound are highlighted in bold.